No Data
No Data
'As Bird Flu Affects More People And Animals, CDC Urges Faster Testing' - Washington Post
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
Pfizer sold shares of Haleon, cashing in 2.5 billion British Pound, reducing its holdings by more than half to 7.3%.
The American pharmaceutical giant Pfizer announced on Wednesday that it has sold 0.7 billion shares of the UK consumer health business company Haleon for 2.5 billion British Pounds (approximately 3.05 billion USD). Pfizer stated that these shares were sold at a price of 357 pence per share, which is a discount of 2.75% from Tuesday's closing price of 367.10 pence per share. Later on Tuesday, Pfizer announced it would sell these shares through a book-building process. After the sale, the company's stake will decrease from 15% to 7.3% of Haleon's issued capital. Haleon owns Sensodyne toothpaste.
JNJ, GSK, LLY Announce M&A Deals at JP Morgan Conference
Pfizer to Cut Haleon Stake in 700M Share Sale
ELIQUENT Life Sciences Announces: Wendy Sanhai, Ph.D., MBA, Joins ELIQUENT Board of Directors